A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis
Authors:
- Michael E. JacobsonMJMichael E. Jacobson
- Ian A. MylesIMIan A. Myles
- Amy S. PallerAPAmy S. Paller
- Lawrence F. EichenfieldLELawrence F. Eichenfield
- Eric Lawrence SimpsonESEric Lawrence Simpson
- 14 August 2023
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 240 (1) , 85-94
Abstract
Background: Atopic dermatitis is a common chronic, relapsing, and remitting inflammatory skin disorder associated with cutaneous dysbiosis. Current treatment options often fail to adequately control the disease and have unfavorable safety profiles. There is a need for new options that address these treatment shortcomings. Objective: The aim of the study was to evaluate the efficacy, safety, and tolerability of FB-401, a live therapeutic product of 3 strains of Roseomonas mucosa, compared to matching placebo applied topically 3 times per week to participants ages ≥2 years of age with mild-to-moderate atopic dermatitis. Methods: A randomized, double-blind, placebo-controlled, parallel-group study was conducted. The primary outcome was the proportion of participants with 50% improvement in Eczema Area and Severity Index score from baseline at week 16. 154 subjects aged 2 or older with a clinical diagnosis of atopic dermatitis as defined by Hanifin and Rajka criteria with mild or moderate severity were randomized 1:1 via interactive web response system to FB-401 or placebo. Results: The proportion of subjects who achieved the primary outcome was similar between both treatment groups, with no significant treatment group differences observed at any post-baseline visit. The number of treatment-emergent adverse events and the number of subjects with at least one were similar across treatment groups. One serious adverse event not related to treatment was reported. No treatment-emergent adverse events led to treatment discontinuation or study discontinuation. Conclusions: FB-401 showed an acceptable safety profile but failed to prove superior to placebo in treating children and adults with mild-to-moderate atopic dermatitis.Keywords
This publication has 17 references indexed in Scilit:
- The microbiome in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2019
- First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitisJCI Insight, 2018
- Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitisPLOS ONE, 2018
- Transplantation of human skin microbiota in models of atopic dermatitisJCI Insight, 2016
- A method for culturing Gram-negative skin microbiotaBMC Microbiology, 2016
- Atopic dermatitisThe Lancet, 2016
- Moisturizing treatment of patients with atopic dermatitis and ichthyosis vulgaris improves dry skin, but has a modest effect on gene expression regardless of FLG genotypeJournal of the European Academy of Dermatology and Venereology, 2013
- Prevalence of atopic dermatitis in Japanese infants treated with moisturizer since birth and its relation to FLG mutationsEuropean Journal Of Dermatology, 2013
- The skin microbiomeNature Reviews Microbiology, 2011
- Novel Antibacterial and Emollient Effects of Coconut and Virgin Olive Oils in Adult Atopic DermatitisDermatitis®, 2008